Business
Industry rush on GLP‑1 weight‑loss drugs may threaten insulin focus, experts warn
Experts say pharma attention on GLP‑1 obesity medicines risks drawing resources away from diabetes supplies, potentially affecting access to insulin in low‑income countries, according to Guardian reports.
2 sources
